I am a
Home I AM A Search Login

Papers of the Week


Papers: 22 Feb 2020 - 28 Feb 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Feb 24


J Headache Pain


21


1

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.

Authors

Lipton RB, Lombard L, Ruff DD, Krege JH, Loo L S, Buchanan A, Melby TE, Buse DC
J Headache Pain. 2020 Feb 24; 21(1):20.
PMID: 32093628.

Abstract

Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety study.